Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ:SNGX)

3.644 -1.316 (-26.54%)
Streaming Delayed Price Updated: 10:26 AM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Soligenix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Loop Industries (Nasdaq: LOOP) Unveils Game-Changing Twist™ Polyester Made Entirely from Textile Waste – More Stocks Inside
Via AB Newswire
Topics Economy Emissions Energy
What's going on in today's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity.
Get a pulse on the US markets on Thursday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity. 
Via Chartmill
Crude Oil Falls 1%; Meta Earnings Top Views
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Thursday's session: gap up and gap down stocks
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday. 
Via Chartmill
Nasdaq Surges Over 1%; Microsoft Posts Upbeat Earnings
 
Via Benzinga
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Achieves Biological Efficacy in Phase 2a SGX945 Study for Behçet’s Disease
Via Investor Brand Network
Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial
Soligenix reports positive Phase 2a trial results for SGX945 in Behçet's disease, showing strong efficacy and no adverse events compared to apremilast. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
BioMedNewsBreaks — Targeting the Unmet: Soligenix Inc. (NASDAQ: SNGX) Building Portfolio for Rare Conditions
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Pioneering Oral Mucositis Treatment with Novel Therapeutic, Promising Study Results
Via Investor Brand Network
Global Vaccination Goals at Risk as 14 Million Kids Miss Crucial Shots
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial
Via Investor Brand Network
InvestorNewsBreaks – Zacks Research Releases Updated Report as Soligenix Inc. (NASDAQ: SNGX) Eyes Upcoming ‘Key Catalysts’
Via Investor Brand Network
Dutch Startup Develops Highly Sensitive Field Test for Infectious Diseases
Via Investor Brand Network
Topics Climate Change
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Multiple 2025–2026 Catalysts Across Rare Disease Pipeline
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Highlights Encouraging Phase 3 Progress for HyBryte(TM) in Investment Webinar
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Research Finds That Pesticides Disrupt Inflammation-Linked Bacteria
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Novel Immunotherapy to Combat Antibiotic Resistance
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Soligenix Inc. (NASDAQ: SNGX) Proprietary Therapy Shows Promise in Treatment of Psoriasis
Via Investor Brand Network
Study Finds the Overall Prevalence of Psoriasis in the US Unchanged
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Programs, Eyes Critical Trial Results in 2025–2026
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.